{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:42:19Z","timestamp":1784799739600,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early antiretroviral therapy (ART) during pregnancy has dramatically reduced the risk of perinatal HIV transmission. However, studies have shown an association between premature delivery and the use of ART during pregnancy (particularly protease inhibitor (PI)-based therapies), which could be explained by placental dysfunction. The objective of this study was to evaluate the association of ART (class, duration of exposure and time of initiation) with placental function by using angiogenic factors placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) as biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical and biological data from 159 pregnant women living with HIV were analyzed. Levels of each biomarker were measured in the first and second trimester of pregnancy. After logarithmic transformation, we compared these using generalized estimating equations according to (a) the type of ART; (b) the duration of exposure to ART; and (c) the time of initiation of ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After adjusting for variables such as ethnicity, maternal age, gestational age, body mass index, parity, smoking status, and sex of the fetus, we found no significant association between the class of ART (PI-based or not) and serum concentrations of PlGF or sFlt-1. Furthermore, no significant association was found between biomarker levels and the duration of ART exposure or the timing of ART initiation (pre- or post-conception).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that first and second trimester angiogenic factor levels are not significantly associated with ART, regardless of the duration or type (with or without PI). These observations seem reassuring when considering the use of ART during early pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-019-2600-4","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T10:03:13Z","timestamp":1575885793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["No association between early antiretroviral therapy during pregnancy and plasma levels of angiogenic factors: a cohort study"],"prefix":"10.1186","volume":"19","author":[{"given":"Ameyo","family":"Djeha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Kakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Soudeyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand","family":"Lapointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9545-6024","authenticated-orcid":false,"given":"Isabelle","family":"Boucoiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"2600_CR1","volume-title":"Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic","author":"UNAIDS","year":"2017","unstructured":"UNAIDS. Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. 2017 Available from: http:\/\/www.unaids.org\/en\/resources\/documents\/2017\/UNAIDS_FactSheet."},{"issue":"1","key":"2600_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jogc.2017.06.033","volume":"40","author":"M Loutfy","year":"2018","unstructured":"Loutfy M, Kennedy VL, Poliquin V, Dzineku F, Dean NL, Margolese S, et al. No. 354-Canadian HIV pregnancy planning guidelines. J Obstet Gynaecol Can. 2018;40(1):94\u2013114.","journal-title":"J Obstet Gynaecol Can"},{"key":"2600_CR3","doi-asserted-by":"crossref","unstructured":"Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;(7):CD003510. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21735394.","DOI":"10.1002\/14651858.CD003510.pub3"},{"key":"2600_CR4","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2019","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services; 2019 updated July 10, 2019. Available from: https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf."},{"key":"2600_CR5","volume-title":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV: World Health Organization","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV: World Health Organization; 2015 Available from: https:\/\/www.who.int\/hiv\/pub\/guidelines\/earlyrelease-arv\/en\/"},{"key":"2600_CR6","volume-title":"EACS Guidelines, version 8.2","author":"J Lundgren","year":"2015","unstructured":"Lundgren J, Gatell J, Rockstroh J, Furrer H. EACS Guidelines, version 8.2 2015 Available from: http:\/\/www.eacsociety.org\/guidelines\/guidelines-archive\/archive.html."},{"key":"2600_CR7","volume-title":"BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update)","author":"L Waters","year":"2016","unstructured":"Waters L, Ahmed N, Angus B, Boffito M, Bower M, Churchill D, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) 2016 Available from: https:\/\/www.bhiva.org\/file\/RVYKzFwyxpgiI\/treatment-guidelines-2016-interim-update.pdf"},{"issue":"13","key":"2600_CR8","first-page":"1671","volume":"168","author":"DR Burdge","year":"2003","unstructured":"Burdge DR, Money DM, Forbes JC, Walmsley SL, Smaill FM, Boucher M, et al. Canadian consensus guidelines for the management of pregnant HIV-positive women and their offspring. CMAJ. 2003;168(13):1671\u20134.","journal-title":"CMAJ."},{"issue":"8","key":"2600_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/j.1471-0528.1998.tb10227.x","volume":"105","author":"P Brocklehurst","year":"1998","unstructured":"Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. BJOG Int J Obstet Gynaecol. 1998;105(8):836\u201348.","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"1","key":"2600_CR10","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","volume":"3","author":"CO Wedi","year":"2016","unstructured":"Wedi CO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaar J. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. Lancet HIV. 2016;3(1):e33\u201348.","journal-title":"Lancet HIV"},{"issue":"14","key":"2600_CR11","first-page":"1815","volume":"22","author":"DK Ekouevi","year":"2008","unstructured":"Ekouevi DK, Coffie PA, Becquet R, Tonwe-Gold B, Horo A, Thiebaut R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan. Cote d'Ivoire Aids. 2008;22(14):1815\u201320.","journal-title":"Cote d'Ivoire Aids"},{"issue":"8","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/QAD.0b013e328133884b","volume":"21","author":"CL Townsend","year":"2007","unstructured":"Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. Aids. 2007;21(8):1019\u201326.","journal-title":"Aids."},{"issue":"5","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/COH.0b013e3283632b88","volume":"8","author":"M-L Newell","year":"2013","unstructured":"Newell M-L, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS. 2013;8(5):504\u201310.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"e172222","DOI":"10.1001\/jamapediatrics.2017.2222","volume":"171","author":"R Zash","year":"2017","unstructured":"Zash R, Jacobson DL, Diseko M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr. 2017;171(10):e172222.","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/QAD.0b013e32834db300","volume":"26","author":"M Lopez","year":"2012","unstructured":"Lopez M, Figueras F, Hernandez S, Lonca M, Garcia R, Palacio M, et al. Association of HIV infection with spontaneous and iatrogenic preterm delivery: effect of HAART. Aids. 2012;26(1):37\u201343.","journal-title":"Aids."},{"issue":"7","key":"2600_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/infdis\/jiv389","volume":"213","author":"N Li","year":"2015","unstructured":"Li N, Sando MM, Spiegelman D, Hertzmark E, Liu E, Sando D, et al. Antiretroviral therapy in relation to birth outcomes among HIV-infected women: a cohort study. J Infect Dis. 2015;213(7):1057\u201364.","journal-title":"J Infect Dis"},{"issue":"1","key":"2600_CR17","first-page":"31","volume":"3","author":"FM Alemu","year":"2015","unstructured":"Alemu FM, Yalew AW, Fantahun M, Ashu EE. Antiretroviral therapy and pregnancy outcomes in developing countries: a systematic review. Int J MCH AIDS. 2015;3(1):31\u201343.","journal-title":"Int J MCH AIDS"},{"issue":"4","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/infdis\/jir307","volume":"204","author":"KM Powis","year":"2011","unstructured":"Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204(4):506\u201314.","journal-title":"J Infect Dis"},{"key":"2600_CR19","doi-asserted-by":"publisher","unstructured":"Mohammadi H, Papp E, Cahill L, Rennie M, Banko N, Pinnaduwage L, et al. HIV antiretroviral exposure in pregnancy induces detrimental placenta vascular changes that are rescued by progesterone supplementation. Sci Rep. 2018;8:6552. https:\/\/doi.org\/10.1038\/s41598-018-24680-w. https:\/\/www.nature.com\/articles\/s41598-018-24680-w#citeas.","DOI":"10.1038\/s41598-018-24680-w"},{"issue":"11","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1593\/neo.06535","volume":"8","author":"N Pore","year":"2006","unstructured":"Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF\/HIF-1\u03b1 expression and angiogenesis in Glioblastoma cells. Neoplasia. 2006;8(11):889\u201395.","journal-title":"Neoplasia."},{"key":"2600_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nm0302-225","volume":"8","author":"C Sgadari","year":"2002","unstructured":"Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8:225.","journal-title":"Nat Med"},{"issue":"3","key":"2600_CR22","first-page":"259","volume":"74","author":"E Lecarpentier","year":"2016","unstructured":"Lecarpentier E, Vieillefosse S, Haddad B, Fournier T, Leguy M-C, Guibourdenche J, et al. Le facteur de croissance placentaire (PlGF) et son r\u00e9cepteur soluble (sFlt-1) au cours de la grossesse: physiologie, dosage et int\u00e9r\u00eat dans la pr\u00e9eclampsie. Ann Biol Clin. 2016;74(3):259\u201367.","journal-title":"Ann Biol Clin"},{"issue":"7","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating Angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672\u201383.","journal-title":"N Engl J Med"},{"issue":"10","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1056\/NEJMoa055352","volume":"355","author":"RJ Levine","year":"2006","unstructured":"Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble Endoglin and other circulating Antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992\u20131005.","journal-title":"N Engl J Med"},{"issue":"1","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejogrb.2013.05.021","volume":"170","author":"N Govender","year":"2013","unstructured":"Govender N, Naicker T, Rajakumar A, Moodley J. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):100\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"287.e1","DOI":"10.1016\/j.ajog.2013.01.016","volume":"208","author":"T Chaiworapongsa","year":"2013","unstructured":"Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, et al. Maternal plasma concentrations of angiogenic\/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013;208(4):287.e1\u2013e15.","journal-title":"Am J Obstet Gynecol."},{"issue":"1","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14767050701830480","volume":"21","author":"R Romero","year":"2008","unstructured":"Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9\u201323.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"2600_CR28","doi-asserted-by":"publisher","first-page":"89.e1","DOI":"10.1016\/j.ajog.2016.01.168","volume":"215","author":"K Baltajian","year":"2016","unstructured":"Baltajian K, Bajracharya S, Salahuddin S, Berg AH, Geahchan C, Wenger JB, et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016;215(1):89.e1\u2013e10.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"782.e1","DOI":"10.1016\/j.ajog.2016.07.056","volume":"215","author":"AM Holme","year":"2016","unstructured":"Holme AM, Roland MCP, Henriksen T, Michelsen TM. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Am J Obstet Gynecol. 2016;215(6):782.e1\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1067\/mob.2003.111","volume":"188","author":"RN Taylor","year":"2003","unstructured":"Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188(1):177\u201382.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3109\/14767058.2011.625458","volume":"25","author":"RS Mijal","year":"2012","unstructured":"Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012;25(7):1135\u201341.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"12","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3109\/14767051003681121","volume":"23","author":"R Romero","year":"2010","unstructured":"Romero R, Chaiworapongsa T, Erez O, Tarca AL, Gervasi MT, Kusanovic JP, et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med. 2010;23(12):1384\u201399.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"5","key":"2600_CR33","doi-asserted-by":"publisher","first-page":"594.e1","DOI":"10.1016\/j.ajog.2016.06.007","volume":"215","author":"LB Andersen","year":"2016","unstructured":"Andersen LB, Dechend R, Karumanchi SA, Nielsen J, Joergensen JS, Jensen TK, et al. Early pregnancy angiogenic markers and spontaneous abortion: an Odense Child Cohort study. Am J Obstet Gynecol. 2016;215(5):594.e1\u2013e11.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"2600_CR34","doi-asserted-by":"publisher","first-page":"629.e1","DOI":"10.1016\/j.ajog.2015.11.015","volume":"214","author":"SJ Korzeniewski","year":"2016","unstructured":"Korzeniewski SJ, Romero R, Chaiworapongsa T, Chaemsaithong P, Kim CJ, Kim YM, et al. Maternal plasma angiogenic index-1 (placental growth factor\/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. Am J Obstet Gynecol. 2016;214(5):629.e1\u2013e17.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"S9.e1","DOI":"10.1016\/j.ajog.2015.08.003","volume":"213","author":"CWG Redman","year":"2015","unstructured":"Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213(4):S9.e1\u20134.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.ajog.2015.08.042","volume":"213","author":"SJ Fisher","year":"2015","unstructured":"Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 2015;213(4):S115\u2013S22.","journal-title":"Am J Obstet Gynecol."},{"issue":"6","key":"2600_CR37","doi-asserted-by":"publisher","first-page":"684.e1","DOI":"10.1016\/j.ajog.2017.10.003","volume":"217","author":"AL Conroy","year":"2017","unstructured":"Conroy AL, McDonald CR, Gamble JL, Olwoch P, Natureeba P, Cohan D, et al. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol. 2017;217(6):684.e1\u2013e17.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2600_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"3","key":"2600_CR39","doi-asserted-by":"publisher","first-page":"359.e1","DOI":"10.1016\/j.ajog.2016.04.002","volume":"215","author":"J Yang","year":"2016","unstructured":"Yang J, Pearl M, DeLorenze GN, Romero R, Dong Z, Jelliffe-Pawlowski L, et al. Racial-ethnic differences in midtrimester maternal serum levels of angiogenic and antiangiogenic factors. Am J Obstet Gynecol. 2016;215(3):359.e1\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2600_CR40","doi-asserted-by":"publisher","first-page":"e0159592","DOI":"10.1371\/journal.pone.0159592","volume":"11","author":"JL Browne","year":"2016","unstructured":"Browne JL, Klipstein-Grobusch K, Koster MP, Ramamoorthy D, Antwi E, Belmouden I, et al. Pregnancy associated plasma protein-a and placental growth factor in a sub-Saharan African population: a nested cross-sectional study. PLoS One. 2016;11(8):e0159592.","journal-title":"PLoS One"},{"key":"2600_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jri.2016.05.005","volume":"117","author":"LB Andersen","year":"2016","unstructured":"Andersen LB, J\u00f8rgensen JS, Herse F, Andersen MS, Christesen HT, Dechend R. The association between angiogenic markers and fetal sex: implications for preeclampsia research. J Reprod Immunol. 2016;117:24\u20139.","journal-title":"J Reprod Immunol"},{"issue":"3","key":"2600_CR42","doi-asserted-by":"publisher","first-page":"247.e1","DOI":"10.1016\/j.ajog.2014.03.020","volume":"211","author":"CA Zera","year":"2014","unstructured":"Zera CA, Seely EW, Wilkins-Haug LE, Lim K-H, Parry SI, TF ME. The association of body mass index with serum angiogenic markers in normal and abnormal pregnancies. Am J Obstet Gynecol. 2014;211(3):247.e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2600_CR43","doi-asserted-by":"publisher","first-page":"244.e1","DOI":"10.1016\/j.ajog.2010.10.001","volume":"204","author":"RS Mijal","year":"2011","unstructured":"Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol. 2011;204(3):244.e1\u2013e12.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2600_CR44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/uog.7548","volume":"35","author":"T Kasdaglis","year":"2010","unstructured":"Kasdaglis T, Aberdeen G, Turan O, Kopelman J, Atlas R, Jenkins C, et al. Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies. Ultrasound Obstet Gynecol. 2010;35(3):280\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"1","key":"2600_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1081\/PRG-120028286","volume":"23","author":"T Krauss","year":"2004","unstructured":"Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with Normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy. 2004;23(1):101\u201311.","journal-title":"Hypertens Pregnancy"},{"key":"2600_CR46","doi-asserted-by":"publisher","first-page":"2632637","DOI":"10.1155\/2018\/2632637","volume":"2018","author":"M Portelli","year":"2018","unstructured":"Portelli M, Baron B. Clinical presentation of preeclampsia and the diagnostic value of proteins and their methylation products as biomarkers in pregnant women with preeclampsia and their newborns. J Pregnancy. 2018;2018:2632637.","journal-title":"J Pregnancy"},{"issue":"2","key":"2600_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.preghy.2013.01.004","volume":"3","author":"C Saffer","year":"2013","unstructured":"Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens. 2013;3(2):124\u201332.","journal-title":"Pregnancy Hypertens"},{"issue":"5","key":"2600_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/uog.14811","volume":"45","author":"A Tsiakkas","year":"2015","unstructured":"Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides K. Gynecology. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. J Ultrasound in Obstetrics. 2015;45(5):591\u20138.","journal-title":"J Ultrasound in Obstetrics"},{"issue":"3","key":"2600_CR49","doi-asserted-by":"publisher","first-page":"239. e1","DOI":"10.1016\/j.ajog.2006.10.909","volume":"196","author":"LJ Vatten","year":"2007","unstructured":"Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196(3):239. e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"9","key":"2600_CR50","doi-asserted-by":"publisher","first-page":"A17","DOI":"10.1016\/j.placenta.2014.06.058","volume":"35","author":"E Papp","year":"2014","unstructured":"Papp E, Mohammadi H, Serghides L. Changes in placental vasculature and pregnancy outcomes in HIV-antiretroviral drug exposed mice. Placenta. 2014;35(9):A17.","journal-title":"Placenta."},{"issue":"5","key":"2600_CR51","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5830\/CVJA-2013-029","volume":"24","author":"N Govender","year":"2013","unstructured":"Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and anti-angiogenic factors in HIV-infected women with pre-eclampsia: cardiovascular topics. Cardiovasc J Africa. 2013;24(5):174\u20139.","journal-title":"Cardiovasc J Africa"},{"issue":"5","key":"2600_CR52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1097\/QAI.0b013e318286d77e","volume":"62","author":"KM Powis","year":"2013","unstructured":"Powis KM, McElrath TF, Hughes MD, Ogwu A, Souda S, Datwyler SA, et al. High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy (HAART) in pregnancy in the Mma Bana study, Botswana. J Acquir Immune Defic Syndr. 2013;62(5):517.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9340","key":"2600_CR53","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S0140-6736(02)11195-0","volume":"360","author":"R Wimalasundera","year":"2002","unstructured":"Wimalasundera R, Larbalestier N, Smith J, De Ruiter A, Thom SM, Hughes A, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 2002;360(9340):1152\u20134.","journal-title":"Lancet"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-019-2600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12884-019-2600-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-019-2600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T19:37:24Z","timestamp":1607369844000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-019-2600-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1186\/s12884-019-2600-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13379\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13379\/v1","asserted-by":"object"}]},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of the CMIS database and biobank for this study was approved by the directors of the CMIS (FK and NL) and the Research Ethics Committee of CHU Sainte-Justine. All participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IB, HT and FK were the recipients of salary awards (chercheur-boursier) from FRQ-S. HT was the recipient of a New Investigator salary award from the Canadian Institutes of Health Research (CIHR). The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"482"}}